Tag: healthcare

The electronic-grade sulfuric acid market is projected to grow at a 6.60% CAGR from 2025-2030 due to increased semiconductor demand. With 96% purity, it cleans and etches wafer chips, vital for semiconductor industry growth. Major regions include Asia-Pacific and the Americas, with key players like BASF and Thermo Fisher Scientific. The report offers valuable insights for businesses on market trends, competitive landscapes, and growth opportunities across various sectors like automotive and healthcare.

Recognized for innovation and inclusion, Mosaicx debuts next-generation Engage platform and earns Best Workplace for Gender Equity Award

-  Prenetics adopts proven corporate Bitcoin strategy inspired by MicroStrategy's ~$40B Bitcoin holdings and Metaplanet's meteoric treasury transformation

PALM BEACH, Fla., June 18, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The market for abuse-deterrent opioids is still developing, but it's estimated that replacing extended-release opioids with abuse-deterrent formulations could lead to significant cost savings and a reduction in abuse-related medical events. While specific revenue figures for the abuse-deterrent opioid market are not readily available, the potential impact on the broader opioid market is substantial. One such report from Roots Analysis, however, did project revenues, saying: “The abuse deterrent formulations market is estimated to grow from USD 25.7 million in 2024 to reach USD 39.8 million in 2025 and USD 54.8 million by 2030, representing a higher CAGR of 6.6% during the forecast period. Although the healthcare industry relies on patient to take medications responsibly, in 2017, close to 18 million individuals were reported to have misused prescription drugs, in the US. In fact, data from a National Survey on Drug Use and Health conducted in the same year, showed that an estimated 2 million Americans misused prescription pain relievers for the first time in the previous year. Moreover, the same study reported 1.5 million people abusing tranquilizers, over 1 million abusing prescription stimulants and more than 270,000 abusing sedatives, for the first time, in the same time period. Owing to a rapid onset of medicinal effect, which offers immediate relief (with high efficacy), opioids are still considered to be one of the most widely used pharmacological interventions for pain management. However, these drugs are known to induce a euphoric state upon consumption, often causing patients to abuse them; increased recreational use of opioids is known to lead to addiction. Moreover, over-prescription of such medicinal products, which promotes their misuse, is considered as one of the root causes of the opioid crisis (increasing number of deaths involving misuse and addiction to opioids), in the US. According to the Centers for Disease Control and Prevention (CDC), more than 72,000 overdose-related deaths were reported in 2017, of which close to 50,000 involved the use of an opioid.”   Active healthcare/tech companies active in the markets include: Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), Pfizer Inc. (NYSE: PFE), Collegium Pharmaceutical, Inc. (NASDAQ: COLL), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Emergent BioSolutions Inc. (NYSE: EBS).

The global patient handling equipment market is set to grow from USD 12.4 billion in 2025 to USD 16.4 billion by 2030, at a CAGR of 5.8%. Key growth drivers include the aging population and rising prevalence of cardiovascular diseases, necessitating advanced and ergonomic devices. A surge in home healthcare services across North America, Europe, and Asia Pacific further boosts demand. The patient transfer devices segment, particularly patient lifts, dominates due to increasing awareness and musculoskeletal injuries among healthcare staff. The Asia Pacific region, driven by countries like China and India, is predicted to grow significantly. Leading companies include Arjo, Stryker, and Baxter International.

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS^® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.